Medical Oncology


Questions discussed in this category

For example, gastric GIST, < 5 mitoses/hpf and size > 5 cm but < 10 cm is intermediate by NIH criteria but low by NCCN/CAP criteria.  Th...

Would your recommendations change in the neoadjuvant versus adjuvant or metastatic setting?

How do you choose between local therapy (surgical debulking or ablation) v. 2nd line systemic therapy? Would you consider immunotherapy?

Papers discussed in this category

JAMA Oncol,

The Lancet. Oncology, 2009-11

Ann. Surg. Oncol., 2015 Feb 05